Harold J Burstein

14PUBLICATIONS
123CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Apr 03, 2024
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.

Carmine Valenza, Dario Trapani, Sibylle Loibl

|Mar 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Erica L Mayer, Yue Ren, Nikhil Wagle

|Mar 13, 2024
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

Harold J Burstein, Angela DeMichele, Lesley Fallowfield

|Nov 29, 2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Erica L Mayer, Nabihah Tayob, Siyang Ren

Pageof 3

Frequent Collaborators

6 joint publications

Angela DeMichele

4 joint publications

Kathy Miller

4 joint publications

Eric P Winer

4 joint publications

Meredith M Regan